Foresee Pharmaceuticals’ oral therapy mirivadelgat has been selected to enter the Phase 2a SLEIPNIR platform trial, which is testing…
Andrea Lobo
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo
People with Parkinson’s disease who switched to the approved oral therapy Crexont, an extended-release formulation of carbidopa and…
Montara Therapeutics received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded Lysoway Therapeutics $3.4 million in funding to support…
More than 2,000 potential participants have been identified for screening in a Parkinson’s clinical trial, thanks to the Parkinson’s…
Patient enrollment has started in a Phase 2a clinical trial evaluating Jotrol, an oral formulation of resveratrol developed by…
Biogen and Denali Therapeutics have ended their clinical development of BIIB122 for people with idiopathic Parkinson’s disease…
A team of researchers in Germany has developed an immuno-infrared sensor (iRS) designed to detect misfolded alpha-synuclein, a protein linked…
Herantis Pharma will use a system based on smartphone technology to measure symptom changes in a Phase 2 trial…
The first participant has been dosed in Vertero Therapeutics’ Phase 1b clinical trial…